Lv4
490 积分 2023-04-04 加入
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
1个月前
已完结
Multispecific T-cell engagers attract cancer drug developers
2个月前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
5个月前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
5个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
6个月前
已完结
Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease
7个月前
已完结
Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy
8个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
9个月前
已完结
Developing cell therapies for lupus
9个月前
已完结
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
9个月前
已完结
皖公网安备34019202002308
